Focusing on macrophage modulation via colony-stimulating factor 1 receptor (CSF1-R) inhibition, PLX3397—an oral, brain-penetrant small-molecule inhibitor—was evaluated in a phase II clinical trial for patients with recurrent GBM [79]. The gene discussed is CSF1R; the disease is glioblastoma.